tetano
Editor, Senior Moderator
Eur J Immunol
. 2020 May 21.
doi: 10.1002/eji.202048693. Online ahead of print.
Prevention and Treatment of COVID-19 Disease by Controlled Modulation of Innate Immunity
Virgil Schijns[SUP] 1 2 [/SUP], Ed C Lavelle[SUP] 3 [/SUP]
Affiliations
Abstract
The recent outbreak of coronavirus disease 2019 (COVID-19), triggered by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) poses an enormous threat to global public health and economies. Human coronaviruses normally cause no or mild respiratory disease but in the past two decades, potentially fatal coronavirus infections have emerged, causing respiratory tract illnesses such as pneumonia and bronchitis. These include severe acute respiratory syndrome coronavirus (SARS-CoV), followed by the Middle East respiratory syndrome coronavirus (MERS-CoV), and recently the SARS-CoV-2 coronavirus outbreak which emerged in Wuhan, China, in December 2019. Currently, most COVID-19 patients receive traditional supportive care including breathing assistance. To halt the ongoing spread of the pandemic SARS-CoV-2 coronavirus and rescue individual patients, established drugs and new therapies are under evaluation. Since it will be some time until a safe and effective vaccine will be available, the immediate priority is to harness innate immunity to accelerate early antiviral immune responses. Secondly since excessive inflammation is a major cause of pathology, targeted anti-inflammatory responses are being evaluated to reduce inflammation-induced damage to the respiratory tract and cytokine storms. Here, we highlight prominent immunotherapies at various stages of development which aim for augmented anti-coronavirus immunity and reduction of pathological inflammation. This article is protected by copyright. All rights reserved.
Keywords: COVID-19; SARS-CoV-2; cytokine; innate immunity; lung.
. 2020 May 21.
doi: 10.1002/eji.202048693. Online ahead of print.
Prevention and Treatment of COVID-19 Disease by Controlled Modulation of Innate Immunity
Virgil Schijns[SUP] 1 2 [/SUP], Ed C Lavelle[SUP] 3 [/SUP]
Affiliations
- PMID: 32438473
- DOI: 10.1002/eji.202048693
Abstract
The recent outbreak of coronavirus disease 2019 (COVID-19), triggered by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) poses an enormous threat to global public health and economies. Human coronaviruses normally cause no or mild respiratory disease but in the past two decades, potentially fatal coronavirus infections have emerged, causing respiratory tract illnesses such as pneumonia and bronchitis. These include severe acute respiratory syndrome coronavirus (SARS-CoV), followed by the Middle East respiratory syndrome coronavirus (MERS-CoV), and recently the SARS-CoV-2 coronavirus outbreak which emerged in Wuhan, China, in December 2019. Currently, most COVID-19 patients receive traditional supportive care including breathing assistance. To halt the ongoing spread of the pandemic SARS-CoV-2 coronavirus and rescue individual patients, established drugs and new therapies are under evaluation. Since it will be some time until a safe and effective vaccine will be available, the immediate priority is to harness innate immunity to accelerate early antiviral immune responses. Secondly since excessive inflammation is a major cause of pathology, targeted anti-inflammatory responses are being evaluated to reduce inflammation-induced damage to the respiratory tract and cytokine storms. Here, we highlight prominent immunotherapies at various stages of development which aim for augmented anti-coronavirus immunity and reduction of pathological inflammation. This article is protected by copyright. All rights reserved.
Keywords: COVID-19; SARS-CoV-2; cytokine; innate immunity; lung.